Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2009

View Archived Issues

Sanofi-aventis reviews 2008 developments

Novel modulator of muscarinic M1 receptor alleviates cognitive deficit in rodents

Telbivudine shows better efficacy than lamivudine in hepatitis B patients

Chelsea Therapeutics successfully completes phase II trial of CH-1504 in RA

Synergistic effects seen with ZSET-1446 and donepezil in cognitive impairment model

BioPorto Diagnostics launches ELISA kit for measuring APC-PCI biomarker

BEMA buprenorphine to proceed to phase II following favorable results

FDA Advisory Committee recommends approval of Multaq for arrhythmia

OSI submits sNDA for Tarceva as first-line maintenance therapy in NSCLC

Biokine initiates Israeli phase I/IIa clinical study of BKT-140 for myeloma

NeuroSearch claims novel 1,4-diaza-bicyclo[3.3.3]nonyl oxadiazolyl derivatives

Antiepileptic drug shows efficacy in neuropathic pain

Roche prepares and tests novel leukotriene B4 antagonists

Novel PPARalpha ligands discovered by Nagoya Industrial Science Research Institute

CytRx announces efficacy results for iroxanadine in rat model of diabetic peripheral neuropathy

Novel heterocyclic compounds developed by Merck & Co. for the treatment of diabetes

Benefit seen in most symptomatic atopic asthma patients with AMG-317

Small ciliary neurotrophic factor peptides designed to improve cognition

Tapentadol IR found safer than oxycodone IR for the treatment of pain

Novartis patents novel beta-secretase inhibitors

Lux completes enrollment into second phase III LUCIDA clinical trial of Lumitect

Evolva commences phase I clinical trials on EV-077-3201-2TBS

FDA approves once-yearly Reclast to treat steroid-induced osteoporosis

Neoprobe's phase III Lymphoseek study achieves positive results

CHMP adopts negative opinion for aztreonam lysine in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...